News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Novartis’s Kymriah CAR-T therapy did not meet its primary endpoint of event-free survival in a phase 3 study in patients with aggressive B-cell non-Hodgkin lymphoma (NHL) after relapse or lack of response to first-line treatment.
Sweden’s Biotage says its expanded facility in the UK will allow it to triple its production capacity for equipment crucial in the supply chain for the production of mRNA vaccines, and thus eliminating a bottleneck for COVID-19 vaccines.
Lonza is to install a new drug product fill and finish manufacturing line at its Guangzhou site in China.
Full approval for the Pfizer BioNTech COVID-19 vaccine, announced by the FDA yesterday, has spurred hopes that more people will take up the vaccine.